Sobi has acquired the licencing rights to market and distribute Tigenix’s product ChondroCelect.
The product is a cell-based medicinal product for the repair of cartilage defects of the knee. Sobi will continue to market and distribute the product in Belgium, the Netherlands and Spain, where it is currently available. The company will also work to expand the product’s availability to patients in a wider area, including the rest of the European Union, Norway, Russia, Switzerland, Turkey, and the countries in the Middle East and North Africa.
“ChondroCelect is an exciting therapy, and we are proud to expand our offering to orthopaedic patients,” said Anders Edvell, MD, PhD, and Vice President Sobi Partner Products. “This partnership is an excellent fit with Partner Products’ strategy for achieving sustainable patient access to new and innovative treatments with a pan-European scope.”